Log in Join free

Open access

Combined talimogene laherparepvec and binimetinib in NRAS-mutated melanoma induces anti-tumor immunity.

Tony Yao Rita E. Chen Melissa M. Yamada J. Moore M. Jimenez Tammy Huang Lynn Cornelius G. Ansstas N. Saligrama David Y. Chen

Sep 2026 · Journal of Clinical Investigation · 0 citations

Medicine

Abstract

<jats:p/>

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Open access Oct 2026

Metronomic decitabine with venetoclax offers a patient-centered frontline therapeutic approach for TP53-mutated complex-karyotype myeloid neoplasms.

Not available.

L. Walsh, Royce P. Lee, Joanathan Pan et al. · Haematologica · 0 citations

Open access Oct 2026

Beyond venetoclax and azacitidine: CD70-targeted triplet therapy in acute myeloid leukemia.

Not available.

S. Garciaz · Haematologica · 0 citations

Docking study of Abexinostat and Acalabrutinib chemotherapeutic anti-cancer agents for non-Hodgkin lymphoma, including mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic as well as for B-cell lymphoma

Majid Monajjemi, F. Mollaamin · 0 citations

Open access Sep 2026

Combination therapy with nelarabine, pegaspargase, and venetoclax for adult patients with R/R T-cell ALL/LBL

Visual Abstract

Niranjan Khaire, Elias J. Jabbour, T. Kadia et al. · Blood neoplasia · 0 citations

Open access Aug 2026

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy

<strong>A prime resistance mechanism of glioblastoma to temozolomide is a vulnerability to radiation therapy</strong>

Vlad Moisoiu, Roxanne Lourman, Frank Szulzewsky et al. · Journal of Clinical Investig... · 0 citations

Open access Sep 2026

DLBCL2IDCS: transdifferentiation of diffuse large B-cell lymphoma to interdigitating dendritic cell sarcoma.

Not available.

Kylie Rose Everard, M. Turingan, Ingrid S. Tam et al. · Haematologica · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.